Table 2 Patients’ clinical characteristics post-treatment, by recovery of platelet counts
Characteristics | PLT ≥ 60 × 109/L (N = 42) | PLT < 60 × 109/L (N = 75) | P | PLT ≥ 100 × 109/L (N = 27) | PLT < 100 × 109/L (N = 90) | P | ||||
|---|---|---|---|---|---|---|---|---|---|---|
N | Median (range) | N | Median (range) | N | Median (range) | N | Median (range) | |||
Age(years) | 68.5(60–87) | 66(60–84) | 0.458 | 69(60–87) | 66(60–84) | 0.619 | ||||
Sex | 0.706 | 0.435 | ||||||||
Male | 22 | 42 | 13 | 51 | ||||||
Female | 20 | 33 | 14 | 39 | ||||||
ECOG | 0.076 | 0.18 | ||||||||
0–2 | 38 | 58 | 25 | 71 | ||||||
≥3 | 4 | 17 | 2 | 19 | ||||||
Diagnosis | 0.305 | 0.771 | ||||||||
M0 | 0 | 3 | 0 | 3 | ||||||
M1 | 9 | 10 | 3 | 16 | ||||||
M2 | 22 | 35 | 14 | 43 | ||||||
M4 | 2 | 6 | 2 | 6 | ||||||
M5 | 5 | 13 | 5 | 13 | ||||||
M6 | 2 | 8 | 2 | 8 | ||||||
Unknown | 2 | 0 | 1 | 1 | ||||||
Primary karyotype | 0.202 | 0.525 | ||||||||
Good | 0 | 1 | 0 | 1 | ||||||
Intermediate | 36 | 53 | 23 | 66 | ||||||
Poor | 4 | 14 | 3 | 15 | ||||||
Unavailable | 2 | 7 | 1 | 8 | ||||||
FLT3-ITD mutation | 0.81 | 0.681 | ||||||||
Positive | 4 | 9 | 2 | 11 | ||||||
Negative | 34 | 54 | 22 | 66 | ||||||
Missing | 4 | 12 | 3 | 13 | ||||||
NPM1 mutation | 0.609 | 0.722 | ||||||||
Positive | 10 | 14 | 5 | 19 | ||||||
Negative | 28 | 50 | 19 | 59 | ||||||
Missing | 4 | 11 | 3 | 12 | ||||||
CEBPα mutation | 0.126 | 0.107 | ||||||||
Positive | 9 | 7 | 7 | 9 | ||||||
Negative | 29 | 52 | 17 | 64 | ||||||
Missing | 4 | 16 | 3 | 17 | ||||||
C-Kit mutation | 1.000 | 1.000 | ||||||||
Positive | 2 | 2 | 1 | 3 | ||||||
Negative | 36 | 58 | 23 | 71 | ||||||
Missing | 4 | 15 | 3 | 16 | ||||||
Initial CBC | ||||||||||
WBC (×109/L) | 11.575 (0.3–310.3) | 6.23 (0.7–239.24) | 0.475 | 4.02 (0.3–196.8) | 9.29 (0.7–310.3) | 0.452 | ||||
Hb (×g/L) | 89.5 (56–128) | 81 (47–139) | 0.097 | 89 (57–113) | 82 (47–139) | 0.785 | ||||
PLT (×109/L) | 56.5 (8–804) | 43 (9–575) | 0.106 | 72 (8–804) | 44 (9–789) | 0.167 | ||||